Teva to cut thousands of U.S. jobs; Regeneron drops Eylea combo drug development; insurers, drugstores, and hospitals increasingly teaming up
FDA presents ideas to tackle drug prices; patients aware of side effects more likely to report them; scientists use Apple's Research Kit for clinical purposes
Brian Goff is expected to replace Carsten Thiel in June. The drugmaker said Tuesday that Thiel along with several other execs would be leaving the firm.
Recent grads aren't afraid to voice their expectations, and agencies are responding with new programs and policies.
Trump puts pharma on notice over drug prices; Mylan lays off nearly 10% of its workforce; Pfizer slapped with U.K. antitrust fine
Doctors tell investment firm Leerink they don't anticipate upping their prescriptions of the new Ellipta line.
Despite drugmaker discount, VA still can't afford Sovaldi without additional funds; Ousted Sanofi CEO Viehbacher faces lawsuit for an alleged kickback scheme; GSK slims sales and R&D workforce.
J&J sells off its feminine side; Manhattan Research's study on the sales rep "tablet dance"; Cepheid rolls out a consumer TB campaign; and healthcare sector job losses top out in July.
Roche is shuttering a division and eliminating 170 jobs; Doximity has added another client; a cautiously-worded study indicates antidepressants may be linked to autism; and NICE has endorsed a new use for Bayer's Xarelto.
Gwee exchanges Edelman offices for Chandler Chicco's, Pfizer can't shake Celebrex lawsuits, FDA issues draft guidance for biosimilars meetings, Dainippon Sumitomo acquires Edison Pharmaceuticals, CDC reports on growing ADHD diagnoses.
Days after announcing a sharp downsizing, the patent expiry-plagued company said it will eliminate an additional 2,300 jobs, raising the tally of cuts to more than 5,000 through 2016.
Healthcare PR giant Dan Edelman dies; Pfizer says 'no comment' on breakup speculation; Publicis Healthcare snags a new SVP; Lippincott gives nurses a new drug diagnosis tool.
ComScore finds a trend between ads and prescriptions, Pfizer is courting fewer PCPs, Weldon is out as chair in 2013.
Bristol-Myers fires, Regeneron hires.
Boston Scientific's new CEO takes office, Watson creates a generics management team
Sandy halts earnings reports and trading, Pfizer and J&J slash headcounts, TGaS to-do's for market researchers, Roche probed on pharmacovigilance
The company talked R&D investment strategies for the two new companies during its Q3 earnings call, and has also laid off 550 employees.
MM&M's 26th annual Career & Salary Survey is now open. Help us to give you the truest picture of salaries, opportunities, migration, aspirations and opinions within pharma and healthcare marketing.
Waggener Edstrom hires a new VP and account exec, MedImmune to shutter two California sites.
Abbott will trim its workforce by approximately 1,900 positions in a restructuring exercise intended to streamline commercial and manufacturing operations. Abbott's US pharmaceutical business will shoulder most of the job cuts, which will happen over the next several years, a company spokesperson said.
Pfizer announced on Sunday that CEO Jeff Kindler has retired from the company, and that Ian Read, Pfizer's head of biopharmaceutical operations, will step into the role as president, CEO and director.
Effective January 1, Novartis will reduce its US field force by 1,400 positions, the firm said, as it braces for patent expiries and shifts resources for product launches.
Roche detailed its "operational excellence" cost-cutting program in a statement today, which includes a reduction of 2,650 pharmaceutical sales and marketing jobs. In total, 6,300 jobs will be affected by the restructuring.
Sanofi-Aventis will winnow its US sales forces down by 1,400, the company announced on Friday. The move follows layoffs in April of around 400 reps, and brings the total sales force headcount down to roughly 4,000. The Paris-based company employed approximately 6,500 US-based reps just one year ago.
California-based Cypress Bioscience ended its co-promotion agreement with Forest Laboratories on Savella (milnacipran), a fibromyalgia drug approved in January 2009. As a result, Cypress will cut 123 jobs.
Following a full-scale realignment of its commercial model in 2009, Novartis will make new adjustments to its US pharmaceutical operations, including a change at the top: Ludwig Hantson, CEO and head of North American pharmaceuticals, will exit the company, a Novartis spokeswoman confirmed.
Eight weeks after the completion of Merck's merger with Schering-Plough, the new company is making staff cuts while hinting of more in commercial and manufacturing areas.
Sanofi-Aventis is laying off 750, or nearly 12%, of its US sales reps, as the firm retrenches in the face of generic exposure on some of its lead products.
IMS Health announced a streamlining of business operations in the wake of second quarter losses, which may include as many as 850 job losses.